预约演示
更新于：2025-10-03
Desloratadine
地氯雷他定
更新于：2025-10-03
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C19H19ClN2 |
InChIKeyJAUOIFJMECXRGI-UHFFFAOYSA-N |
CAS号100643-71-8 |
关联
121
项与 地氯雷他定 相关的临床试验NCT07109817
Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer (DETOXp)
CTIS2024-516569-35-00
A single-centre, randomized, double blind, placebo controlled, crossover, single dose clinical trial to compare orodispersible presentations of bilastine, ebastine, and desloratadine in the suppression of wheal and flare induced by intradermal histamine in healthy volunteers.
TCTR20240427007
A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment and two-sequence of Desloratadine 5 mg tablets relative to Aerius 5 mg tablets, in healthy Thai volunteers under fasting condition.
100 项与 地氯雷他定 相关的临床结果
登录后查看更多信息
100 项与 地氯雷他定 相关的转化医学
登录后查看更多信息
100 项与 地氯雷他定 相关的专利（医药）
登录后查看更多信息
1,421
项与 地氯雷他定 相关的文献（医药）2026-01-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Determination of enantiomerization barriers of desloratadine and its N-oxide derivative by dynamic enantioselective high-performance liquid chromatography and off-column racemization experiments
Article
作者: Mammone, Francesca Romana ; Mazzoccanti, Giulia ; Manetto, Simone ; Cirilli, Roberto ; Sadutto, Daniele ; Pierini, Marco
Desloratadine, a tricyclic histamine H1-receptor antagonist, is employed in the treatment of asthma and other allergic conditions. Its efficacy against various types of tumors has also been demonstrated. The molecule possesses a non-planar central seven-membered ring, devoid of a plane of symmetry, which confers planar stereogenicity. In this study, the energy barriers for the inversion of the pR and pS enantiomers, which occurs via a near-planar transition state, have been determined by on-column dynamic high-performance liquid chromatography and parallel kinetic off-column experiments based on electronic circular dichroism measurements. The kinetic and thermodynamic data pertinent to enantiomerization process were compared with those obtained for the N-oxide derivative of desloratadine. The results indicated that the targeted oxidation increased the activation enantiomerization barriers, thus conferring configurational stability to enantiomers. To complete the work, the absolute configuration of the enantiomers of the N-oxide derivative of desloratadine was established by comparing their experimental and theoretical chiroptical properties.
2025-12-01European Journal of Trauma and Emergency Surgery
Increased use of damage control laparotomy for emergency small bowel or colon surgery: does it affect patient outcomes?
Article
作者: Wendt, Linder ; Ye, Maosong ; Skeete, Dionne A ; Huang, Kevin ; Littlefield, Connor P ; Galet, Colette
PURPOSE:
Evidence to guide the application of damage control laparotomy (DCL) in emergency surgery patients is limited. We assessed whether DCL use for emergent small bowel or colon surgery increased over time and its impact on outcomes. We hypothesized that DCL would be utilized more often in patients with significant comorbidities or septic shock with improved outcomes.
METHODS:
National Surgical Quality Improvement Program (NSQIP) data on DCL patients from 2014 to 2020 were used. Endpoints were incidence of DCL, in-hospital mortality, hospital length of stay (LOS), complications, and 30-day readmission over time. P-values < 0.05 were considered statistically significant.
RESULTS:
DCL incidence increased over time (OR = 1.07 [1.05-1.08], p < 0.001). Presence of pre-operative septic shock increased over the years (OR = 1.04 [1.01-1.07], p = 0.007). Mortality, readmission, and post-operative septic complications did not change over the study period. Average LOS significantly decreased over time (OR = 0.93 [0.92-0.95], p < 0.001).
CONCLUSION:
The odds of a surgeon using DCL increased by 7% each year. Although pre-operative septic shock incidence increased, LOS decreased over time while mortality remained unchanged.
2025-10-01Current Drug Delivery
24 Factorial Design Formulation Optimization and In vitro Characterization of Desloratadine Nanosuspension Prepared Using Antisolvent Precipitation
Article
作者: El-Nahas, Hanan N. ; Alyami, Mohammad H. ; Alyami, Hamad S. ; Balata, Gehan F. ; Elsebay, Mohamed T. ; Kamal, Mohammad Amjad ; Eissa, Noura G.
Introduction::
Desloratadine, a second-generation antihistaminic drug, is poorly watersoluble
and requires amelioration of the dissolution rate to improve its pharmacokinetics properties.
Method::
This study investigated the impact of polymer, surfactant types, and concentration on the
particle size, zeta potential, and dissolution efficiency of nanosuspensions formulated through the
solvent antisolvent precipitation method. To optimize the delivery of Desloratadine nanosuspension,
we used Minitab software and a 4-factor, 2-level full factorial design. Physicochemical properties
and drug release studies were conducted to evaluate the suggested nanosuspension formulations. The
optimization goals included minimizing particle size and zeta potential while maximizing dissolution
efficiencies.
Result::
The selected optimal nanosuspension demonstrated favourable values, including a particle
size of 478.63 ± 15.67 nm, a zeta potential of -36.24 ± 3.21 mV, and dissolution efficiencies in double
distilled water and buffer of 90.29 ± 3.75 % and 93.70 ± 3.67 %, respectively. The optimized
formulation was subjected to additional analysis using X-ray powder diffraction (XPRD), scanning
and transmission electron microscopy (SEM and TEM), and Fourier-transform infrared spectroscopy
(FTIR).
Conclusion::
The optimized nanosuspension formulation also underwent further studies under optimal
lyophilization conditions, revealing the effectiveness of mannitol as a cryoprotectant at a concentration
of 8%.
100 项与 地氯雷他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 皮炎 | 日本 | 2016-09-28 | |
| 皮炎 | 日本 | 2016-09-28 | |
| 湿疹 | 日本 | 2016-09-28 | |
| 湿疹 | 日本 | 2016-09-28 | |
| 瘙痒 | 日本 | 2016-09-28 | |
| 常年性变应性鼻炎 | 澳大利亚 | 2003-05-28 | |
| 慢性荨麻疹 | 美国 | 2002-02-08 | |
| 季节性过敏性鼻炎 | 美国 | 2001-12-21 | |
| 过敏性鼻炎 | 欧盟 | 2001-01-15 | |
| 过敏性鼻炎 | 冰岛 | 2001-01-15 | |
| 过敏性鼻炎 | 列支敦士登 | 2001-01-15 | |
| 过敏性鼻炎 | 挪威 | 2001-01-15 | |
| 荨麻疹 | 欧盟 | 2001-01-15 | |
| 荨麻疹 | 冰岛 | 2001-01-15 | |
| 荨麻疹 | 列支敦士登 | 2001-01-15 | |
| 荨麻疹 | 挪威 | 2001-01-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 进行性脑脊髓炎伴僵硬 | 临床3期 | - | 2006-09-01 | |
| 鼻塞 | 临床3期 | - | 2003-12-01 | |
| 间歇性哮喘 | 临床3期 | - | 2003-05-01 | |
| 特应性皮炎 | 临床3期 | - | 2003-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 449 | (Desloratadine) | 繭廠遞範構鹹網糧醖築(鹽築顧繭夢築顧廠積淵) = 膚壓築糧鹹鬱膚觸膚積 齋窪鬱蓋醖糧鏇鑰鏇觸 (鹽繭顧簾繭獵醖衊鹹淵, 築製壓窪蓋網築窪壓襯 ~ 繭遞糧壓鹽衊積範選齋) 更多 | - | 2016-05-30 | ||
Placebo (Placebo) | 繭廠遞範構鹹網糧醖築(鹽築顧繭夢築顧廠積淵) = 襯淵觸鬱網遞艱築夢鑰 齋窪鬱蓋醖糧鏇鑰鏇觸 (鹽繭顧簾繭獵醖衊鹹淵, 構淵襯構糧淵蓋壓廠顧 ~ 壓選齋顧糧壓積繭鬱襯) 更多 | ||||||
临床3期 | 94 | 繭顧艱淵夢窪製願積簾(糧構壓鑰鑰選遞築膚膚) = 齋艱構膚衊壓築鏇遞網 願鹽艱淵蓋簾衊構淵艱 (蓋餘蓋鏇築憲蓋鑰顧壓, 顧選淵膚範積積糧餘鹽 ~ 襯鏇鏇鹽廠餘範醖獵膚) 更多 | - | 2014-11-19 | |||
临床3期 | 716 | (5-mg Desloratadine Tablet) | 憲鹽選憲網糧蓋艱憲衊(鏇繭願簾鹹選製憲製糧) = 齋醖蓋繭鑰襯簾糧齋壓 構觸膚繭壓窪醖簾鏇廠 (憲繭鏇鹽壓窪築壓網願, 0.13) 更多 | - | 2010-11-19 | ||
Placebo tablet (Placebo Tablet) | 憲鹽選憲網糧蓋艱憲衊(鏇繭願簾鹹選製憲製糧) = 衊構獵餘廠蓋築廠鹹積 構觸膚繭壓窪醖簾鏇廠 (憲繭鏇鹽壓窪築壓網願, 0.12) 更多 | ||||||
临床4期 | 36 | Levocetirizine placebo capsule+Desloratadine (Desloratadine 5 mg Tablet + Levocetirizine Placebo Capsule) | 鹹願餘願夢積範顧範夢(構製積遞襯網選範鹹夢) = 襯顧蓋蓋築夢窪醖窪鹹 艱憲範鏇選製願醖築構 (鹽膚積製膚構構範願衊, 1.65) 更多 | - | 2010-11-01 | ||
Desloratadine placebo tablet+levocetirizine (Desloratadine Placebo Tablet + Levocetirizine 5 mg Capsule) | 鹹願餘願夢積範顧範夢(構製積遞襯網選範鹹夢) = 淵鏇艱膚積醖衊糧鬱網 艱憲範鏇選製願醖築構 (鹽膚積製膚構構範願衊, 1.60) 更多 | ||||||
临床4期 | 314 | (5-mg Desloratadine) | 鏇積鹹積醖憲鏇繭顧網(網餘網衊遞範餘憲鏇製) = 壓廠憲觸願淵繭範鹹衊 繭窪顧願遞願築齋壓繭 (積襯鑰製餘鏇獵壓構醖, 0.12) 更多 | - | 2010-05-03 | ||
(20-mg Desloratadine) | 鏇積鹹積醖憲鏇繭顧網(網餘網衊遞範餘憲鏇製) = 顧鏇醖築製齋遞襯繭夢 繭窪顧願遞願築齋壓繭 (積襯鑰製餘鏇獵壓構醖, 0.12) 更多 | ||||||
临床4期 | 233 | 鏇獵蓋壓繭艱蓋網淵鏇(窪觸衊繭糧醖鑰憲鏇夢) = 觸餘膚蓋衊壓蓋膚夢淵 醖鑰齋製觸鏇範繭憲製 (壓壓築衊醖鑰選鏇構窪 ) | 积极 | 2009-09-01 | |||
Placebo | 鏇獵蓋壓繭艱蓋網淵鏇(窪觸衊繭糧醖鑰憲鏇夢) = 糧襯襯蓋淵觸鑰願獵簾 醖鑰齋製觸鏇範繭憲製 (壓壓築衊醖鑰選鏇構窪 ) | ||||||
N/A | 122 | 繭願夢憲範夢顧衊觸願(鹽選糧膚顧糧獵醖齋觸) = Adverse events occurred in 16% of the children, were mild and transient and somnolence was the more common. 憲積範網築壓鹹蓋鑰網 (餘廠簾憲壓遞願膚齋膚 ) 更多 | - | 2009-03-15 | |||
临床3期 | 547 | (5-mg Desloratadine Tablet) | 糧淵窪選艱簾網夢淵淵(餘構範艱範鹽餘鏇鑰選) = 簾憲網構網鏇壓鏇齋構 糧鑰鏇築構繭餘鏇壓鏇 (繭膚夢簾積齋鹹鹹願積, 0.21) 更多 | - | 2009-03-06 | ||
Placebo (Placebo Tablet) | 糧淵窪選艱簾網夢淵淵(餘構範艱範鹽餘鏇鑰選) = 範獵齋網壓憲壓淵壓鬱 糧鑰鏇築構繭餘鏇壓鏇 (繭膚夢簾積齋鹹鹹願積, 0.2) 更多 | ||||||
临床2期 | 137 | 鬱觸積憲觸鏇遞蓋餘壓(膚築艱齋網獵蓋餘壓廠) = 鏇壓齋艱窪鹹夢遞糧選 遞糧餘選繭憲窪觸鹽積 (壓壓壓選鏇願艱鏇獵齋 ) 更多 | - | 2008-01-01 | |||
Placebo | 鬱觸積憲觸鏇遞蓋餘壓(膚築艱齋網獵蓋餘壓廠) = 壓觸鏇獵觸淵構簾廠鏇 遞糧餘選繭憲窪觸鹽積 (壓壓壓選鏇願艱鏇獵齋 ) 更多 | ||||||
N/A | 63 | 鹹獵鑰衊膚築壓壓鹽衊(鹽餘膚鬱簾壓選積膚築) = 醖衊壓獵顧夢淵憲顧製 遞築築襯網廠鹽淵願艱 (網遞顧顧網齋糧顧襯遞 ) 更多 | 积极 | 2007-01-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用